Strengthening our climate ambitions: Octapharma’s path to net zero

Octapharma strengthened its long-term climate ambitions in 2025. “Setting science-based climate targets is a natural extension of our values and our commitment to sustainability,” said Tobias Marguerre, Deputy Chairman. “As a family-owned company, we see it as our responsibility to act not just for today, but for future generations to come.”

During 2025, Octapharma moved decisively, formalising a Group-wide climate strategy aligned with climate science to contribute to limit global warming to 1.5°C. Octapharma’s strategy is anchored in two science-based targets: a near-term goal to reduce absolute Scope 1, 2 and 3 corporate greenhouse gas emissions by 63% by 2035, and a long-term ambition to achieve a 90% reduction by 2050, reaching net zero across the value chain.

A long-term roadmap to reduce emissions across the business

To support these targets, Octapharma developed a global decarbonisation roadmap in 2025 that sets out how the Group will reduce emissions across its operations and wider value chain over the next 25 years.

Within its own operations (Scope 1 and 2), Octapharma is prioritising energy efficiency, expanded use of renewable electricity, and deployment of modern heating and cooling technologies.

The roadmap also outlines measures to tackle Scope 3 emissions, which make up 85% of the Group’s footprint. These include collaborating with key suppliers on emission-reduction plans, increasing resource efficiency through, for example, increased ethanol redistillation and enhanced recycling, shifting logistics routes from air to sea freight, reducing business flights, and promoting lower-emission commuting options for employees.

Progress in 2025: Building on what we already do

Octapharma maintained its renewable electricity purchases in Europe while expanding renewable electricity sourcing in the United States. Production sites advanced major energy efficiency upgrades, supporting reductions in energy use across operations.

Preparations also advanced for switching to natural refrigerants at several facilities, while work continued on resource efficiency initiatives such as ethanol redistillation in Springe and expanding cold water for injection (cold WFI) systems. The company also reviewed transport modal shifts to reduce air freight on select international routes, in collaboration with logistics partners.

A structured framework for the next decade and beyond

“By setting science-based climate targets backed by an actionable roadmap, Octapharma is taking action to foster a resilient future for people, for the planet and for the business,” said Manuela Huck-Wettstein, Group Director Sustainability.

While many initiatives will require multi-year investment and technological development, the Group emphasises that the roadmap balances ambition with practical implementation and financial responsibility.

The roadmap introduced in 2025 serves as a consistent framework for all Octapharma locations, and provides a structured approach to prioritise projects based on emission reduction potential, implementation feasibility and cost–benefit considerations.

Local and functional teams are now working to translate the global framework into detailed, site-specific action plans. This approach ensures that climate targets are not standalone commitments but embedded into daily operational decision-making across the business.

“This commitment to sustainability builds on Octapharma’s existing environmental initiatives and reflects our strategic approach to sustainable growth,” said Olivier Clairotte, Chief Production Officer.